TNFA_OUT_1 [2025-04-25 11:56:51 -0400] 5627 Bytes | 1388 tokens | Cum: 1388 tkns (17.35% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at TNF Pharmaceuticals (TNFA) which is at $0.2294 up from $0.1920. So, I pulled together a bunch of data for you to look over real fast. It's still early, 11:56 AM on Fri Apr 25, 2025. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: TNF Pharmaceuticals (TNFA)
IPO: 2021-04-19 (4 Years Ago)
Market Cap: $760,398
Shares Outstanding: 2,760,000
Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange: XNAS
Description: TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

Here’s a list of headlines for TNF Pharmaceuticals:

Apr-22-25 09:15AM - TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
Apr-16-25 09:15AM - TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025
Mar-18-25 09:25AM - TNF Pharmaceuticals presents isomyosamine data
Mar-17-25 09:15AM - TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
Mar-05-25 09:00AM - TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
Feb-25-25 09:20AM - TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
Jan-29-25 09:15AM - TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
Jan-15-25 09:15AM - TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
Dec-19-24 09:15AM - TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
Dec-09-24 09:00AM - TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
Oct-02-24 09:10AM - TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
Aug-21-24 09:00AM - TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline
Jul-24-24 09:05AM - TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol TNFA Effective Before Market Open Today
Jul-22-24 09:00AM - MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
Jul-15-24 07:52AM - MYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q1 2024
Jun-17-24 09:00AM - MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
May-21-24 09:00AM - PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
May-21-24 09:00AM 09:00AM - MyMD Pharmaceuticals Secures Strategic Investments
May-17-24 03:52PM - MYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q4 2023
Apr-09-24 08:21AM - Why Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today?
Mar-05-24 09:15AM - MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Feb-13-24 11:45AM - MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-24T17:00:00Z - Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for TNF Pharmaceuticals (TNFA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

TNFA_OUT_3 [2025-04-25 11:56:52 -0400] 1053 Bytes | 257 tokens | Cum: 1647 tkns (20.59% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/24/3067801/0/en/Sarcopenia-Clinical-Trial-Pipeline-Appears-Robust-With-18-Key-Pharma-Companies-Actively-Working-in-the-Therapeutics-Segment-DelveInsight.htmlThe sarcopenia market remains largely untapped, with significant unmet medical needs and no approved drug therapies. However, pharmaceutical interest is rising, particularly around muscle-enhancing agents and anti-inflammatory pathways. Regulatory bodies are beginning to recognize sarcopenia as a distinct clinical condition, which may streamline future drug approvals.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TNFA_OUT_5 [2025-04-25 11:56:53 -0400] 1017 Bytes | 293 tokens | Cum: 1942 tkns (24.27% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-22T19:30:05Z - TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish...
A2 - 2025-04-22T18:46:03Z - TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish By Stoc...
A3 - 2025-04-22T13:18:14Z - TNF Pharmaceuticals (TNFA) and Renova Health Utilize AI to Accelerate Drug Development...
A4 - 2025-04-17T17:05:50Z - 12 Health Care Stocks Moving In Thursday's Intraday Session - Agilon Health (NYSE:AGL), Adagio Medic...
A5 - 2025-04-17T12:09:34Z - 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Forian (NASDAQ:FORA), Channel Therap...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TNFA_OUT_7 [2025-04-25 11:56:54 -0400] 1181 Bytes | 300 tokens | Cum: 2244 tkns (28.05% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish**Date: 2025-04-22Source: {'uri': 'newsable.asianetnews.com', 'dataType': 'news', 'title': 'Asianet News Network Pvt Ltd'}URL: https://newsable.asianetnews.com/markets/tnf-pharmaceuticals-to-use-ai-to-recruit-patients-for-drug-development-retail-stays-bearish/articleshow-wdd1hctsynopsisThe company stated that the TNF-Renova partnership is analyzing data from 30,000 patients to identify high-risk patients.

Shares of TNF Pharmaceuticals, Inc. (TNFA) traded nearly 5% higher on Tuesday afternoon after it announced a partnership with Renova Health for the application of AI and machine learning technologies to recruit patients for its isomyosamine drug development.

Isomyosamine is a drug platform based on a clinical stage small molecule that is being developed to treat diseases and disorders mar

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TNFA_OUT_9 [2025-04-25 11:56:55 -0400] 1181 Bytes | 244 tokens | Cum: 2490 tkns (31.13% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): ked by acute or chronic inflammation.

The clinical-stage pharmaceutical company stated that it would use Renova Health's proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management.

The company stated that the TNF-Renova partnership is analyzing data from 30,000 patients to identify high-risk patients.

Renova CEO David Jacobs said that its technology transcends traditional big data analytics by creating highly specific patient personas.

"Our platform uncovers the nuanced impact of individual physician practices -- such as varying diagnosis codes for GLP-1 prescriptions, like BMI versus diabetes -- which can significantly influence cohort selection and study outcomes," he said.

Isomyosamine is the first of

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TNFA_OUT_11 [2025-04-25 11:56:55 -0400] 1019 Bytes | 244 tokens | Cum: 2736 tkns (34.20% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): two therapeutic platforms being developed by TNF Pharmaceuticals. While Isomyosamine is being developed to regulate inflammation, the company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy.

On Stocktwits, retail sentiment around TNF remained unmoved in the 'bearish' territory over the past 24 hours while message volume remained at 'low' levels.

TNFA stock is down by over 84% so far this year and by over 93% over the past 12 months.

For updates and corrections, email newsroom[at]stocktwits[dot]com<

For latest News subscribe to Asianet News Whatsapp channel by clicking here.For breaking news and more subscribe to Asianet News on YouTube by clicking here.Read Full Article

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TNFA_OUT_13 [2025-04-25 11:56:57 -0400] 1093 Bytes | 304 tokens | Cum: 3042 tkns (38.02% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S4 - 2025-04-11 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The information set forth below should be read in conjunction with our CONS financial statements and related notes thereto included elsewhere in this Annual Report on Form 10-...

S5 - 2025-03-10 8-K Item 7.01 Regulation FD Disclosure.

On March 6, 2025, TNF Pharmaceuticals, Inc. (the Company) held a telephonic conference call to discuss the Companys research and development progress with respect to the Companys lead compound, Isomyosamine. A transcript of the call is attach...

S6 - 2024-11-14 10-Q PART I - Fin Information

I tem 1. Fin Stmnts.

TNF PHARMACEUTICALS, INC. & SUBSIDIARIES

Condensed Cons Balance Sheets

September 30, 2024 and December 31, 2023

(unaudited)

September 30, 2024 December 31, 2023 As of September 30, 2024 December...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TNFA_OUT_15 [2025-04-25 11:56:57 -0400] 1181 Bytes | 250 tokens | Cum: 3294 tkns (41.17% of 8k)
==========================================================================

Showing S4 (chunk 1 of 3): S4:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The information set forth below should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Annual Report on Form 10-K. This discussion and analysis contains forward-looking statements based on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties. Our actual results could differ materially from those indicated in these forward-looking statements as a result of certain factors, including those discussed in Item 1 of this Annual Report on Form 10-K, entitled Business, under Forward-Looking Statements and Item 1A of this Annual Report on Form 10-K, entitled Risk Factors. References in this discussion and analysis to us, we, our, or the Company refer c

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TNFA_OUT_17 [2025-04-25 11:56:58 -0400] 1181 Bytes | 237 tokens | Cum: 3533 tkns (44.16% of 8k)
==========================================================================

Showing S4 (chunk 2 of 3): ollectively to TNF Pharmaceuticals, Inc.

Our financial statements are prepared in accordance with GAAP. These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does not require managements judg

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TNFA_OUT_19 [2025-04-25 11:56:59 -0400] 1077 Bytes | 231 tokens | Cum: 3766 tkns (47.08% of 8k)
==========================================================================

Showing S4 (chunk 3 of 3): ment in its application. There are also areas in which managements judgment in selecting any available alternative would not produce a materially different result. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this Annual Report on Form 10-K.

##TABLE_START 60 ##TABLE_END

This Annual Report on Form 10-K and other reports filed by the Company from time to time with the Securities and Exchange Commission (the SEC and such reports, collectively, the Filings) contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Companys management as well as estimates and assumptions made by Companys management. -- disclaimer trimmed --

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TNFA_OUT_21 [2025-04-25 11:57:05 -0400] 5914 Bytes | 1529 tokens | Cum: 5297 tkns (66.21% of 8k)
==========================================================================

This is our set of metrics for TNF Pharmaceuticals.
Please analyze the numbers.

+-------------------+-----------------------+------------------------+-------------------------+
| Volume: 3,766,908 | Perf Month: -34.79% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 1.14M | Perf Quarter: -80.33% | Short Float: 9.72% | ROE: -169.93% |
+-------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 8.97 | Index: - | Short Ratio: 0.82 | ROI: -184.52% |
+-------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 38.82 | Market Cap: 2.38M | Short Interest: 0.94M | Sales Surprise: -14.63% |
+-------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 0.05 | Shs Outstand: 10.13M | Beta: 2.18 | EPS Surprise: -79.41% |
+-------------------+-----------------------+------------------------+-------------------------+
| SMA20: -17.53% | Shs Float: 9.63M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+------------------------+-------------------------+
| SMA50: -35.48% | Inst Own: 1.51% | Sales past 5Y: 0.00% | Earnings: - |
+-------------------+-----------------------+------------------------+-------------------------+
| SMA200: -80.12% | Insider Own: 4.98% | Employees: 2 | |
+-------------------+-----------------------+------------------------+-------------------------+
| Perf Week: 27.78% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+-------------------+-----------------------+------------------------+-------------------------+

The next section covers any insider trading by TNF Pharmaceuticals officers or majority shareholders (if available).

Inside Trans: TNF Pharmaceuticals, Inc. (TNFA) by Glass Mitchell (President, CMO) on 2025-04-17
- Employee Stock Option (Right to Buy): 125000 shares at $0 (D)

Inside Trans: TNF Pharmaceuticals, Inc. (TNFA) by RAUCH GARY M (Unknown Title) on 2025-04-17
- Employee Stock Option (Right to Buy): 75000 shares at $0 (D)

Inside Trans: TNF Pharmaceuticals, Inc. (TNFA) by RHODES IAN (Interim CFO) on 2025-04-17
- Employee Stock Option (Right to Buy): 25000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -1929391.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.2293
Average Volume: 2254500.41
30-Day High: 0.4419
30-Day Low: 0.1715

[Detailed Financials: Q3 2024]
- Total Assets: $24,043,759.00
- Total Liabilities: $6,988,723.00
- Total Equity: $16,777,343.00
- Current Assets: $12,026,935.00
- Current Liabilities: $6,988,723.00

[Income Statement: Q3 2024]
- Revenue: N/A
- Net Income: $-1,929,391.00
- Gross Profit: N/A
- Operating Income: $-1,825,639.00
- Earnings Per Share (EPS): -1.11

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $656,325.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of TNF Pharmaceuticals (TNFA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about TNF Pharmaceuticals.

2) MARKET_SCORE[]
This conversation was initiated because TNFA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for TNFA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, TNFA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect TNFA to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of TNF Pharmaceuticals.

11) ETHICAL_RATING[]
Rate TNF Pharmaceuticals’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of TNF Pharmaceuticals.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

TNFA_IN_23 [2025-04-25 11:57:05 -0400] 126 Bytes | 29 tokens | Cum: 5510 tkns (68.88% of 8k)
==========================================================================

====================================
[2025-04-25 11:57:05] # Analysis Completed
Elapsed Time: 14.99 seconds